JP2021525083A5 - - Google Patents

Info

Publication number
JP2021525083A5
JP2021525083A5 JP2020565415A JP2020565415A JP2021525083A5 JP 2021525083 A5 JP2021525083 A5 JP 2021525083A5 JP 2020565415 A JP2020565415 A JP 2020565415A JP 2020565415 A JP2020565415 A JP 2020565415A JP 2021525083 A5 JP2021525083 A5 JP 2021525083A5
Authority
JP
Japan
Prior art keywords
composition
sodium phosphate
methionine
sucrose
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565415A
Other languages
English (en)
Japanese (ja)
Other versions
JP7497300B2 (ja
JP2021525083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033983 external-priority patent/WO2019227029A1/en
Publication of JP2021525083A publication Critical patent/JP2021525083A/ja
Publication of JP2021525083A5 publication Critical patent/JP2021525083A5/ja
Priority to JP2024039768A priority Critical patent/JP7832245B2/ja
Application granted granted Critical
Publication of JP7497300B2 publication Critical patent/JP7497300B2/ja
Priority to JP2026033801A priority patent/JP2026086903A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565415A 2018-05-25 2019-05-24 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物 Active JP7497300B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024039768A JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676525P 2018-05-25 2018-05-25
US62/676,525 2018-05-25
PCT/US2019/033983 WO2019227029A1 (en) 2018-05-25 2019-05-24 Pharmaceutical compositions for treating acid sphingomyelinase deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024039768A Division JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2021525083A JP2021525083A (ja) 2021-09-24
JP2021525083A5 true JP2021525083A5 (cg-RX-API-DMAC10.html) 2022-05-26
JP7497300B2 JP7497300B2 (ja) 2024-06-10

Family

ID=66912954

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020565415A Active JP7497300B2 (ja) 2018-05-25 2019-05-24 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2024039768A Active JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A Pending JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024039768A Active JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A Pending JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Country Status (15)

Country Link
US (1) US20210145941A1 (cg-RX-API-DMAC10.html)
EP (1) EP3802805A1 (cg-RX-API-DMAC10.html)
JP (3) JP7497300B2 (cg-RX-API-DMAC10.html)
KR (1) KR102852946B1 (cg-RX-API-DMAC10.html)
CN (1) CN112424347A (cg-RX-API-DMAC10.html)
AU (2) AU2019275109C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020023829A2 (cg-RX-API-DMAC10.html)
CA (1) CA3101688A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014399A2 (cg-RX-API-DMAC10.html)
IL (1) IL278964A (cg-RX-API-DMAC10.html)
MX (2) MX2020012700A (cg-RX-API-DMAC10.html)
PY (1) PY1939780A (cg-RX-API-DMAC10.html)
SG (1) SG11202011488WA (cg-RX-API-DMAC10.html)
UY (1) UY38238A (cg-RX-API-DMAC10.html)
WO (1) WO2019227029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022214529A1 (en) * 2021-02-01 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of niemann pick type a disease
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
CN1897957A (zh) * 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
AU2007226582B2 (en) * 2006-03-13 2012-07-05 Revvity Health Sciences, Inc. Substrates and internal standards for mass spectroscopy detection
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
JP6073783B2 (ja) * 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
MX338436B (es) 2011-03-31 2016-04-18 Medy Tox Inc Preparacion liofilizada de toxinas de botulismo.
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Similar Documents

Publication Publication Date Title
FI3294345T3 (fi) Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi
JP2012523414A5 (cg-RX-API-DMAC10.html)
Ropper et al. Limited relapse in Guillain-Barré syndrome after plasma exchange
EP2628484B9 (en) Platelet-rich plasma compositions
JP2024069459A5 (cg-RX-API-DMAC10.html)
JPWO2019156137A5 (cg-RX-API-DMAC10.html)
CN104043098A (zh) 一种用于治疗妇女阴道炎的抗菌肽冻干制剂及制备方法
JP2019533722A5 (cg-RX-API-DMAC10.html)
JP2010501596A5 (cg-RX-API-DMAC10.html)
CN107802645A (zh) 稀土元素喷剂
US20090182055A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
JP2005506275A5 (cg-RX-API-DMAC10.html)
JP2021504349A5 (cg-RX-API-DMAC10.html)
CN104940994B (zh) 一种人造鼻粘膜及其用途
CN1160123C (zh) 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物
RU2024125372A (ru) Фармацевтические композиции для лечения недостаточности кислой сфингомиелиназы
RU2020142782A (ru) Фармацевтические композиции для лечения недостаточности кислой сфингомиелиназы
CN108125979A (zh) 一种具有杀菌保护功能的组合物及其应用
CN118831041A (zh) 一种纳米酶凝胶及其制备方法和应用
TWI773927B (zh) 促進及治療慢性傷口癒合之組合物及方法
CN103923208B (zh) 一种重组人角质细胞生长因子-2突变体的活性稳定剂
CN104208189A (zh) 治疗复发性口腔溃疡的中药制剂
CN104771384A (zh) 紫草素的医药用途
Park et al. Esophageal achalasia compressing left atrium diagnosed by echocardiography using a liquid containing carbon dioxide in a 21-year-old woman with Turner syndrome
TW202116347A (zh) 肽及其作為製備治療發炎性疾病及疼痛的藥物的用途